1) Aged =18 years old at the time of enrollment, 2)Be able to comply with the requirements of clinical study protocol and complete all trial procedures, and sign informed consent form, 3)Subjects who have not received any COVID-19 vaccine(marketed or investigational), those who have received at least one dose of other COVID-19 vaccines (marketed or investigational) with an interval of =6 months between the last dose and the date when the subjects sign the informed consent for this study, 4)Those who are negative for HIV screening (depending on the relevant policy of the country where the trial is conduct, if qualification for HIV testing is required in the country, this information will be obtained mainly by inquiry while protecting the candidate’s privacy) 5)Fertile males and females of childbearing potential who are willing to take appropriate contraceptive measures from signing ICF to 3 months after the last dose, including abstinence or effective contraceptive measures (e.g., intrauterine or implantable contraceptive devices, oral contraception, combination of contraceptive diaphragm or condom with contraceptive gel), women of childbearing potential should be negative for pregnancy test on the day of vaccination. 6)Healthy people or people with a mild underlying disease that has remained stable without exacerbation (not requiring hospitalization or without major modification of the treatment regimen) within at least 3 months prior to inclusion in the study

1) Aged =18 years old at the time of enrollment, 2)Be able to comply with the requirements of clinical study protocol and complete all trial procedures, and sign informed consent form, 3)Subjects who have not received any COVID-19 vaccine(marketed or investigational), those who have received at least one dose of other COVID-19 vaccines (marketed or investigational) with an interval of =6 months between the last dose and the date when the subjects sign the informed consent for this study, 4)Those who are negative for HIV screening (depending on the relevant policy of the country where the trial is conduct, if qualification for HIV testing is required in the country, this information will be obtained mainly by inquiry while protecting the candidate’s privacy) 5)Fertile males and females of childbearing potential who are willing to take appropriate contraceptive measures from signing ICF to 3 months after the last dose, including abstinence or effective contraceptive measures (e.g., intrauterine or implantable contraceptive devices, oral contraception, combination of contraceptive diaphragm or condom with contraceptive gel), women of childbearing potential should be negative for pregnancy test on the day of vaccination. 6)Healthy people or people with a mild underlying disease that has remained stable without exacerbation (not requiring hospitalization or without major modification of the treatment regimen) within at least 3 months prior to inclusion in the study